Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Procedure: Apheresis
Procedure: Stem Cell Transplantation
Drug: Melphalan

First Posted Date: 2009-08-31

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00968396

Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

Phase 2

Withdrawn

Conditions: Cutaneous T-cell Lymphoma

Interventions: Drug: Curcumin (Turmeric)
Behavioral: Questionnaires
Other: Photos

First Posted Date: 2009-08-31

Last Posted Date: 2012-09-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00969085

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Leukemia

Interventions: Drug: Everolimus (RAD001)
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Mesna
Drug: Methotrexate
Drug: Ara-C (Cytarabine)
Drug: Methylprednisone
Drug: G-CSF

First Posted Date: 2009-08-28

Last Posted Date: 2019-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00968253

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2009-08-28

Last Posted Date: 2013-03-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 71

Registration Number: NCT00968071

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Phase 2

Completed

Conditions: Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions: Drug: Bortezomib
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide

First Posted Date: 2009-08-27

Last Posted Date: 2020-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00967369

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Panobinostat
Drug: Everolimus

First Posted Date: 2009-08-27

Last Posted Date: 2015-02-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00967044

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Lenalidomide
Drug: Thalidomide

First Posted Date: 2009-08-27

Last Posted Date: 2020-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 77

Registration Number: NCT00966693

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Phase 4

Completed

Conditions: Pancreatic Cancer
Venous Thromboembolism

Interventions: Drug: Dalteparin

First Posted Date: 2009-08-26

Last Posted Date: 2016-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 87

Registration Number: NCT00966277

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

Phase 3

Completed

Conditions: Advanced Cancer

Interventions: Drug: Testosterone
Drug: Placebo

First Posted Date: 2009-08-25

Last Posted Date: 2016-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00965341

Locations: 🇺🇸
The DeBakey VA Medical Center/Baylor College of Medicine, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Caphosol in Sarcoma Patients With Mucositis

Phase 2

Completed

Conditions: Sarcoma
Oral Mucositis

Interventions: Other: Caphosol
Other: Baking Soda

First Posted Date: 2009-08-25

Last Posted Date: 2012-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00965172

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy